Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets

BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics

(2019) Mariana Villalobos-Ortiz et al.   CELL DEATH AND DIFFERENTIATION

In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101

(2019) Laura Masuelli et al.   INVESTIGATIONAL NEW DRUGS

ABT-737 Triggers Caspase-Dependent Inhibition of Platelet Procoagulant Extracellular Vesicle Release during Apoptosis and Secondary Necrosis In Vitro

(2019) Hao Wei et al.   THROMBOSIS AND HAEMOSTASIS

Venetoclax: A new wave in hematooncology

(2018) Jana Mihalyova et al.   EXPERIMENTAL HEMATOLOGY

Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets

(2018) Hao Wei et al.   Scientific Reports

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines

(2018) Delphine Merino et al.   CANCER CELL

Effect of the BH3 Mimetic Polyphenol (–)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma

(2018) Monica Benvenuto et al.   Frontiers in Pharmacology

Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload

(2017) Matthew T. Harper   PLATELETS

BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics

(2016) R. S. Soderquist et al.   MOLECULAR CANCER THERAPEUTICS

Unknown

(2016)   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The BCL-2 protein family, BH3-mimetics and cancer therapy

(2015) A R D Delbridge et al.   CELL DEATH AND DIFFERENTIATION

BCL-2 is dispensable for thrombopoiesis and platelet survival

(2015) M A Debrincat et al.   Cell Death & Disease

Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis

(2015) Shankar Varadarajan et al.   NEOPLASIA

The role of apoptosis in megakaryocytes and platelets

(2014) Benjamin T. Kile   BRITISH JOURNAL OF HAEMATOLOGY

Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation

(2013) R. van Kruchten et al.   BLOOD

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet shrinkage and microparticle formation

(2013) Armen V. Gyulkhandanyan et al.   THROMBOSIS RESEARCH

Bcl-xL-inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores

(2012) M. T. Harper et al.   BLOOD

Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy

(2012) C. Bodur et al.   CURRENT MEDICINAL CHEMISTRY

Cisplatin induces platelet apoptosis through the ERK signaling pathway

(2012) Weilin Zhang et al.   THROMBOSIS RESEARCH

BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation

(2011) M. Vogler et al.   BLOOD

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

(2011) S. M. Schoenwaelder et al.   BLOOD

Doxorubicin-Induced Platelet Procoagulant Activities: An Important Clue for Chemotherapy-Associated Thrombosis

(2011) Se-Hwan Kim et al.   TOXICOLOGICAL SCIENCES

BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins

(2010) Jun Wei et al.   JOURNAL OF MEDICINAL CHEMISTRY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Different forms of cell death induced by putative BCL2 inhibitors

(2009) M Vogler et al.   CELL DEATH AND DIFFERENTIATION